Werner JK, Shahim P, Pucci JU, Chen L, Raiciulescu S, Gill JM, Nakase-Richardson R, Diaz-Arrastia R and Kenney K
Sleep, zsaa272
DOI: https://doi.org/10.1093/sleep/zsaa272
Study Objectives
Sleep disorders affect over half of mild traumatic brain injury (mTBI) patients. Despite evidence linking sleep and neurodegeneration, longitudinal TBI-related dementia studies have not considered sleep. We hypothesized that poor sleepers with mTBI would have elevated markers of neurodegeneration and lower cognitive function compared to mTBI good sleepers and controls. Our objective was to compare biomarkers of neurodegeneration and cognitive function with sleep quality in warfighters with chronic mTBI.
Methods
In an observational warfighters cohort (n=138 mTBI, 44 controls), the Pittsburgh Sleep Quality Index (PSQI) was compared with plasma biomarkers of neurodegeneration and cognitive scores collected an average of 8 years after injury.
Results
In the mTBI cohort, poor sleepers (PSQI≥10, n = 86) had elevated plasma neurofilament light (NfL, x̅ = 11.86 vs. 7.91 pg/mL, p=0.0007, d=0.63) and lower executive function scores by the categorical fluency (x̅ = 18.0 vs 21.0, p=0.0005, d= –0.65) and stop-go tests (x̅ = 30.1 vs 31.1, p=0.024, d = -0.37). These findings were not observed in controls (n = 44). PSQI predicted NfL (Beta=0.22, p=0.00002) and tau (Beta=0.14, p=0.007), but not amyloid β42. Poor sleepers showed higher obstructive sleep apnea (OSA) risk by STOP-BANG scores (x̅ = 3.8 vs 2.7, p=0.0005), raising the possibility that the PSQI might be partly secondary to OSA.
Conclusions
Poor sleep is linked to neurodegeneration and select measures of executive function in mTBI patients. This supports implementation of validated sleep measures in longitudinal studies investigating pathobiological mechanisms of TBI related neurodegeneration, which could have therapeutic implications.
Poster Background Reliable and reproducible antibody barcoding is critical for spatial biology workflows onthe Akoya PhenoCycler®-Fusion 2.0 (PCF). We evaluated and optimized a complementarychemistry to the existing Antibody Conjugation Kit…
Neurology
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Neurology
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
